Appellate Court upholds decision in first-ever non-settlement national RICO class action lawsuit certified against a major ...

With the FDA's approval of hereditary angioedema preventative treatment Andembry, CSL is ready to take on Takeda’s ...

The insomnia therapeutics market size has shown steadfast growth in recent years. From a market value of $3.03 billion in 2024, it is projected to grow to $3.21 billion in 2025, demonstrating a ...

No-moat Takeda Pharmaceutical is Japan’s leading pharmaceutical company by revenue. While the firm historically focused on the Japan market, management has undertaken an ambitious overhaul to ...

In this article, we are going to take a look at where Takeda Pharmaceutical Company Limited (NYSE:TAK) stands against the other pharma stocks. Healthcare, which includes numerous businesses that ...

In this article, we are going to take a look at where Takeda Pharmaceutical Company Limited (NYSE:TAK) stands against the other Japanese stocks. As the dangers of natural disasters increase and ...

Takeda Pharmaceutical Company Limited (NYSE:TAK) Q3 2025 Earnings Call Transcript January 30, 2025 Christopher O’Reilly: [Foreign Language] Let me start, I’d like to remind everyone that we ...